Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rocket Pharmaceuticals Inc RCKT

Healthcare Biotechnology
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic... see more

Recent & Breaking News (NDAQ:RCKT)

Rocket Pharmaceuticals Announces Closing of Public Offering

Business Wire December 13, 2019

Rocket Pharmaceuticals Prices Public Offering of Common Stock

Business Wire December 10, 2019

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Business Wire December 10, 2019

Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 "Process B" for Fanconi Anemia

Business Wire December 6, 2019

Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting

Business Wire December 5, 2019

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

Business Wire November 27, 2019

Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

Business Wire November 7, 2019

Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 "Process B" for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting

Business Wire November 6, 2019

Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit

Business Wire November 5, 2019

Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 "Process A" for Fanconi Anemia

Business Wire October 24, 2019

Rocket Pharmaceuticals Announces Clearance of IND for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency

Business Wire October 22, 2019

Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress

Business Wire October 15, 2019

Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference

Business Wire October 1, 2019

Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency

Business Wire September 23, 2019

Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine

Business Wire September 10, 2019

Rocket Pharmaceuticals Announces First Patient Treated in Phase 1/2 Registrational Trial of RP-L201 for LAD-I

Business Wire September 5, 2019

Rocket Pharmaceuticals Announces Registration-Enabling Phase 2 Plans for RP-L102 Gene Therapy for Fanconi Anemia Following a Supportive End-of-Phase 1 FDA Meeting

Business Wire September 4, 2019

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

Business Wire August 28, 2019

Rocket Pharmaceuticals Announces Clearance from the Spanish Agency for Medicines and Health Products for the Phase 2 Registration-enabling FANCOLEN-II Study of RP-L102 for Fanconi Anemia

Business Wire August 22, 2019

Rocket Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights

Business Wire August 7, 2019